| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.096 | 0.09 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.06 | 0.09 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.056 | 0.1 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | BMS-536924 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | 0.073 | 0.1 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |